Free Trial

Perrigo Q4 2022 Earnings Report

Perrigo logo
$25.44 -0.97 (-3.67%)
(As of 05:44 PM ET)

Perrigo EPS Results

Actual EPS
$0.75
Consensus EPS
$0.70
Beat/Miss
Beat by +$0.05
One Year Ago EPS
$0.60

Perrigo Revenue Results

Actual Revenue
$1.16 billion
Expected Revenue
$1.20 billion
Beat/Miss
Missed by -$45.00 million
YoY Revenue Growth
+4.60%

Perrigo Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Slide Deck

Do this Before Elon’s Reveal on January 22nd (Ad)

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

I urge you to watch this video now.

Perrigo Earnings Headlines

Buffett's Oil Bet + This 22% Dividend Play
Warren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occidental and Chevron) pay modest dividends of 1.47% and 4%, we've found a way for regular investors to potentially earn a much bigger income stream from the energy boom.
PRGO Crosses Above Key Moving Average Level
See More Perrigo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email.

About Perrigo

Perrigo (NYSE:PRGO) provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

View Perrigo Profile

More Earnings Resources from MarketBeat

Upcoming Earnings